Close Menu

NEW YORK (GenomeWeb) – Natera and Swiss biotech Amal Therapeutics plan to partner on a clinical trial to test Natera's bespoke circulating tumor DNA assay, Signatera, to assess treatment response in late-stage colorectal cancer patients.

The prospective clinical trial will assess Amal's cancer vaccine, ATP128, in combination with a PD-1 inhibitor in patients with stage IV colorectal cancer. Study investigators will use Signatera to measure patients' treatment response.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test.